Andrew Roberts
MBBS, PhD
Professor and Clinical Hematologist
👥Biography 个人简介
Andrew Roberts led the first-in-human clinical development of venetoclax in chronic lymphocytic leukemia, translating decades of BCL-2 biology into a transformative therapy. His work defined tumor lysis risk management and combination strategies with rituximab and obinutuzumab. He continues to guide trials expanding venetoclax use in AML and multiple myeloma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Andrew Roberts 的研究动态
Follow Andrew Roberts's research updates
留下邮箱，当我们发布与 Andrew Roberts（Walter and Eliza Hall Institute / Royal Melbourne Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment